Inborn errors of metabolism:

Indications for FABRAZYME:

Fabry disease.

Adults and Children:

<2yrs: not established. Pretreat with antipyretic and antihistamine. Give by IV infusion. ≥2yrs: 1mg/kg every 2 weeks. Initially infuse at a rate of 0.25mg/min; if tolerated, may increase by increments of 0.05–0.08mg/min with each subsequent infusion. <30kg: max rate 0.25mg/min. ≥30kg: minimum duration is 1.5hrs. Slow rate if infusion reactions occur. Rechallenge: initially give a low dose and infusion rate (eg, 0.5mg/kg at 0.01mg/min); once tolerated, may increase dose to 1mg/kg, titrate rate slowly upwards (doubled every 30mins up to max 0.25mg/min); see full labeling.

FABRAZYME Warnings/Precautions:

Have appropriate medical support measures readily available; discontinue immediately if anaphylaxis or severe hypersensitivity reactions occur. Consider testing for IgE antibodies in patients who experienced suspected hypersensitivity reactions; if positive, may be rechallenged. Risk of infusion-associated reactions; if reaction occurs, decrease infusion rate, temporarily discontinue, and consider additional antipyretics, antihistamines, and/or steroids; if severe reactions occur, discontinue immediately. Compromised cardiac function; monitor closely. Pregnancy. Nursing mothers.

FABRAZYME Classification:

Recombinant human alpha-galactosidase A enzyme.

Adverse Reactions:

Upper RTI, chills, pyrexia, headache, cough, paresthesia, fatigue, peripheral edema, dizziness, rash.


Register pregnant patients at or call (800) 745-4447.

Generic Drug Availability:


How Supplied:

Single-use vial—1

Pricing for FABRAZYME

35mg vial (Qty: 1)
Appx. price $6706